ALG 055009
Alternative Names: ALG-009; ALG-055009; ALG-THR-β; THR-Beta agonist - Aligos Therapeutics; THR-β-agonists - Aligos TherapeuticsLatest Information Update: 18 Nov 2025
At a glance
- Originator Aligos Therapeutics
- Class Amides; Amines; Chlorophenols; Ethers; Hepatoprotectants; Obesity therapies; Pyridazines; Small molecules; Triazines
- Mechanism of Action Fibroblast growth factor 21 expression stimulants; Thyroid hormone receptor beta agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- Preclinical Obesity
Most Recent Events
- 06 Nov 2025 Preclinical trials in Obesity in USA (PO) before November 2025
- 06 Nov 2025 Pharmacodynamics data from a preclinical trial in Obesity released by Aligos Therapeutics
- 28 May 2025 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in France (PO)